Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of conivaptan hydrochloride in preparation of medicine for treating feline infectious peritonitis

A conivaptan hydrochloride, infectious technology, applied in the field of preparation of drugs for the treatment of feline infectious peritonitis, can solve the problems of large side effects, can not reduce the high mortality rate of feline infectious peritonitis, and achieve high safety and good curative effect

Active Publication Date: 2020-08-18
武汉都为康生物科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs not only have relatively large side effects, but also can only temporarily delay the disease process with symptomatic treatment, and cannot reduce the high mortality rate of feline infectious peritonitis
[0004] The molecular formula of Conivaptan hydrochkoride is C 32 h 27 ClN 4 o 2 , is a non-peptide dual inhibitor of arginine vasopressin (AVP) V1a and V2 receptors, mainly used for the treatment of normovolemic hyponatremia, and has not been used for the treatment of feline infectious peritonitis related reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of conivaptan hydrochloride in preparation of medicine for treating feline infectious peritonitis
  • Application of conivaptan hydrochloride in preparation of medicine for treating feline infectious peritonitis
  • Application of conivaptan hydrochloride in preparation of medicine for treating feline infectious peritonitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Embodiment 1 conivaptan hydrochloride is to the toxicity test of cell

[0014] 1. Test method

[0015] 1) Take well-growing CCL-94 (cat kidney cells) for digestion and passage, and use cell growth medium to adjust the cell density to 1×10 5 / mL, seeded in a 96-well plate, 100 μL per well, placed at 37°C, 5% CO 2 Cultivate in an incubator for 16 hours;

[0016] 2) After 16 hours, take out the 96-well plate, discard the culture medium in the well, wash three times with sterile PBS, and after drying, add 100 μL of cell maintenance solution to the first column of each group, and add 50 μL cell maintenance solution;

[0017] 3) Make a mark on the lid, add conivaptan hydrochloride to the first column of each group in the order of marking, perform 2-fold dilution, mix gently with a row gun for ten times, suck out 50 μL and add it to the second column, and then By analogy, mix and discard 50 μL at the end. Make the final concentration of conivaptan hydrochloride 200 μM, 10...

Embodiment 2

[0021] Embodiment 2 conivaptan hydrochloride is active TCID to feline coronavirus 50 Determination of

[0022] 1. Test method

[0023] 1) The CCL-94 cells were digested and passaged, and the cell density was adjusted to 1×10 with cell growth medium. 5 / mL, inoculate 2mL / well in 12-well plate, 37℃, 5%CO 2 Cultivate in an incubator for 16 hours;

[0024] 2) Take out the 12-well plate, mark it well, mix the cell maintenance solution with conivaptan hydrochloride so that the final concentrations of conivaptan hydrochloride are 25 μM, 12.5 μM, 6.25 μM, 3.125 μM, 1.5625 μM, and place on a shaker Mix for at least 5 seconds;

[0025] 3) Discard the medium in the wells of the 12-well plate, wash with sterile PBS three times, add the diluted drug after drying, and place at 37°C, 5% CO 2 Incubate for 1 hour in the incubator;

[0026] 4) After 1 hour, take out the 12-well plate, inoculate each well with 0.01 MOI of feline coronavirus, shake the 12-well plate to mix well, set virus c...

Embodiment 3

[0032] The indirect immunofluorescence detection of embodiment 3 conivaptan hydrochloride to feline coronavirus activity

[0033] 1. Test method

[0034] 1) Take CCL-94 cells in good growth state for digestion and passage, and adjust the cell density to 1×10 with cell growth medium. 5 / mL, inoculate 100 μL / well in a 96-well plate, and place at 37°C, 5% CO 2 Cultivate in an incubator for 16 hours;

[0035] 2) After 16 hours, the cells were covered with a single layer, and the 96-well plate was taken out and washed twice with serum-free DMEM medium, replaced with a cell maintenance solution, and the compound was added for 2-fold dilution. The final concentration of conivaptan was 25 μM, 12.5 μM, 6.25 μM, 3.125 μM, and 1.5625 μM, and a virus control group and a cell control group were set at the same time;

[0036] 3) When 60% of the cells have lesions, discard the medium in the well, wash with PBS twice, and then add 4% paraformaldehyde to fix the cells for 30 minutes;

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses use of conivaptan hydrochloride in the preparation of a drug for treating feline infectious peritonitis. Conivaptan hydrochloride has very low toxicity to feline normal cells and has an obvious inhibition effect to feline coronavirus and is capable of obviously reducing virulence of viruses in the cells; an indirect immunofluorescence detection result shows that conivaptanhydrochloride can effectively inhibit the proliferation of the feline coronavirus in the cells and has dose dependence. Therefore, conivaptan hydrochloride can be used for preparing a feline coronavirus inhibitor for treating feline infectious peritonitis and has the advantages of good treatment effect, high safety and the like.

Description

technical field [0001] The invention relates to a new pharmaceutical application of conivaptan hydrochloride, in particular to the application in preparing a medicine for treating feline infectious peritonitis. Background technique [0002] Feline infectious peritonitis is a disease caused by infection with feline coronavirus. It is a chronic, progressive and infectious disease of cats, mainly characterized by peritonitis and massive pleural effusion. The fatality rate of sick cats is high, and most drugs have no therapeutic effect on them, and can only prolong their lives. [0003] The current treatment for feline infectious peritonitis is mainly to use immunosuppressive and anti-inflammatory drugs, such as the use of high doses of steroids, or the use of broad-spectrum antibiotics and antiviral drugs to prevent secondary infection. These drugs not only have relatively large side effects, but also can only temporarily delay the disease process with symptomatic treatment, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/55A61P31/14
CPCA61K31/55A61P31/14
Inventor 彭贵青李慧刘一楠
Owner 武汉都为康生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com